North America Active Pharmaceutical Ingredients (API) Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Apr 2021
  • North America
  • 350 Pages
  • No of Tables: 186
  • No of Figures: 59

North America Active Pharmaceutical Ingredients (API) Market, By Molecule (Small Molecule, Large Molecule), Type (Innovative Active Pharmaceutical Ingredients, Generic Innovative Active Pharmaceutical Ingredients), Type of Manufacturer (Captive API Manufacturer, Merchant API Manufacturer), Synthesis (Synthetic Active Pharmaceutical Ingredients and Biotech Active Pharmaceutical Ingredients), Chemical Synthesis (Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, Tamoxifen, Others), Type of Drug (Prescription Drugs, Over-the-Counter), Usage (Clinical, Research), Potency (Low-to-Moderate Potency Active Pharmaceutical Ingredients, Potent-to-Highly Potent Active Pharmaceutical Ingredient), Therapeutic Application (Cardiology, CNS & Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Other Therapeutic Application), Country (U.S., Mexico, Canada) Industry Trends and Forecast to 2028

North America Active Pharmaceutical Ingredients (API) Market

Market Analysis and Insights: North America Active Pharmaceutical Ingredients (API) Market

The active pharmaceutical ingredients (API) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.2% in the forecast period of 2021 to 2028 and is expected to reach USD 103,457.04 million by 2028. Increasing prevalence of various chronic disorders and increase in aging population are the major drivers which propelled the demand of the active pharmaceutical ingredients (API) market in the forecast period.

In Greek, the traditional word for active pharmaceutical ingredients (API) is called pharmacon or pharmakon which symbolizes a magical substance or drug. Active pharmaceutical ingredients as described in ICH Q7 are “any substance or combination of substances intended to be used in the manufacturing of a drug product which when used in the production of the drug becomes an active pharmaceutical ingredient. Such substances are used to provide pharmacological activity.

Increase in technological advancements will enhance the capabilities and boost the manufacturing skills of the market players that the manufacturers have to provide APIs in bulk and meet the demand of the consumers which can drive the growth of the active pharmaceutical ingredients (API) market. Availability of sub-standard and counterfeit drugs is acting as a restraint for hampering the demand of the active pharmaceutical ingredients (API) market. Rising investment in research regarding the development of APIs will further increase the growth opportunities for the active pharmaceutical ingredients (API) market. Disruption in the supply chain of APIs during COVID-19 acts challenging for the healthcare providers which may challenge the active pharmaceutical ingredients (API) market.

The active pharmaceutical ingredients (API) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the active pharmaceutical ingredients (API) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Active Pharmaceutical Ingredients (API) Market

Active Pharmaceutical Ingredients (API) Market Scope and Market Size

The active pharmaceutical ingredients (API) market is segmented on the basis of the molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of molecule, the active pharmaceutical ingredients (API) market is segmented into small molecule and large molecule. In 2021, small molecule segment is expected to dominate the active pharmaceutical ingredients (API) market due to increasing number of regulatory approval and rising research and development on novel small molecules due to their high penetration power.
  • On the basis of type, the active pharmaceutical ingredients (API) market is segmented into innovative active pharmaceutical ingredients and generic active pharmaceutical ingredients. In 2021, innovative active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of high cost of innovative APIs in comparison to generic APIs and rising FDA approval for the new molecular entities.
  • On the basis of type of manufacturer, the active pharmaceutical ingredients (API) market is segmented into captive API manufacturer and merchant API manufacturer. In 2021, captive API manufacturer segment is expected to dominate the active pharmaceutical ingredients (API) market due to huge investment by major market players to generate high end manufacturing facilities and easy availability of raw materials.
  • On the basis of synthesis, the active pharmaceutical ingredients (API) market is segmented into synthetic active pharmaceutical ingredients and biotech active pharmaceutical ingredients. In 2021, synthetic active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of easy protocol for the synthesis of molecules, less stringent regulatory guidelines and in the coming years, many synthetic molecules goes off patent.
  • On the basis of chemical synthesis, the active pharmaceutical ingredients (API) market is segmented into acetaminophen, artemisinin, saxagliptin, sodium chloride, ibuprofen losartan potassium, enoxaparin sodium, rufinamide, naproxen, tamoxifen and others. In 2021, saxagliptin segment is expected to dominate the active pharmaceutical ingredients (API) market due to high cost of the API and rising diabetes cases worldwide.
  • On the basis of type of drug, the active pharmaceutical ingredients (API) market is segmented into prescription drugs and over-the-counter drugs. In 2021, prescription drugs segment is dominating the active pharmaceutical ingredients (API) market because of high cost of the drugs which will increase the APIs and manufacturing cost of the APIs.
  • On the basis of usage, the active pharmaceutical ingredients (API) market is segmented into clinical and research. In 2021, clinical segment is expected to dominate the active pharmaceutical ingredients (API) market because of rising number of diseases which required continuous supply of APIs and raw material.
  • On the basis of potency, the active pharmaceutical ingredients (API) market is segmented into low-to-moderate potency active pharmaceutical ingredients and potent-to-highly potent active pharmaceutical ingredient. In 2021, low-to-moderate potency active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of their less toxicity and less hazard nature.
  • On the basis of therapeutic application, the active pharmaceutical ingredients (API) market is segmented into cardiology, CNS & neurology, oncology, orthopedic, endocrinology, pulmonology, gastroenterology, nephrology, ophthalmology and other therapeutic application. In 2021, cardiology segment is expected to dominate the active pharmaceutical ingredients (API) market because of rising number of cardiac diseases such as heart attack, embolism and others.

Active Pharmaceutical Ingredients (API) Market Country Level Analysis

The active pharmaceutical ingredients (API) market is analyzed and market size information is provided on the basis of the country, molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application as referenced above.

The countries covered in North America active pharmaceutical ingredients (API) market report are the U.S, Mexico, Canada

Innovative active pharmaceutical ingredients segment in North America region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because increase in research and development for the novel molecule. The U.S. is leading the growth due to technological advancement in manufacturing of APIs.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Prevalence of Various Chronic Disorders is boosting the Growth of Active Pharmaceutical Ingredients (API) Market

The active pharmaceutical ingredients (API) market also provides you with detailed market analysis for every country growth in active pharmaceutical ingredients (API) industry with active pharmaceutical ingredients (API) drugs sales, impact of advancement in the active pharmaceutical ingredients (API) technology and changes in regulatory scenarios with their support for the active pharmaceutical ingredients (API) market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Active Pharmaceutical Ingredients (API) Market Share Analysis

The active pharmaceutical ingredients (API) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to active pharmaceutical ingredients (API) market.

The major companies which are dealing in the active pharmaceutical ingredients (API) are Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline plc., Aarti Industries Limited, Recipharm AB (publ), Jubilant Pharmova Limited, LUPIN, Aurobindo Pharma, Alembic Pharmaceuticals Limited, AbbVie Inc., AstraZeneca, Alkem Labs, Albemarle Corporation, Saneca Pharmaceuticals, Unichem Laboratories, Neuland Laboratories Ltd., Divi's Laboratories Limited., HIKAL Ltd., Viatris Inc. , Merck KGaA, Novo Nordisk A/S, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Minakem, BASF SE, Cipla Inc., CordenPharma International, Piramal Pharma Solutions, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the active pharmaceutical ingredients (API) market.

For instance,

  • In January 2018, AstraZeneca had signed an agreement with Cambrex who is the leading manufacturer of the small molecule APIs. The company has signed the agreement for the long term manufacturing of the products. This agreement helped the company to increase their product portfolio as the manufacturing is for the long term so it will boost the manufacturing skills of the company and at the end the revenues of the company will increase in end.
  • In August 2016, Piramal Pharma Solutions had acquired Ash Stevens Inc which is in the U.S. and is based on the Contract Development and Manufacturing Organization (CDMO). The acquisition was done for the cash price of USD 42.95 million. Ash Stevens is involved in the development and commercialization of the pharmaceuticals to their clients worldwide. This acquisition helped the company to enhance their product portfolio in the terms of API market.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players is enhancing the company market in the active pharmaceutical ingredients (API) market which also provides the benefit for organization to improve their offering for active pharmaceutical ingredients (API).

Customization Available: North America Active Pharmaceutical Ingredients (API) Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, PIPELINE ANALYSIS

TABLE 2 DIFFERENCE BETWEEN THE U.S. AND EU FOR THE REGISTRATION PROCESS

TABLE 3 DIFFERENCE BETWEEN THE U.S. AND EU FOR THE ADMINISTRATIVE REQUIREMENTS

TABLE 4 AGE DISTRIBUTION OF THE U.K. POPULATION (FROM 1976 TO 2046)

TABLE 5 WORLD –WIDE IMPACT OF COVID-19 ON THE PHARMACEUTICAL SECTOR

TABLE 6 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 7 NORTH AMERICA SMALL MOLECULE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 8 NORTH AMERICA LARGE MOLECULE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 9 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 10 NORTH AMERICA INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 11 NORTH AMERICA GENERIC ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 12 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURERS, 2017-2028 (USD MILLION)

TABLE 13 NORTH AMERICA CAPTIVE API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 14 NORTH AMERICA MERCHANT API MANUFACTURER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET , BY REGION, 2017-2028 (USD MILLION)

TABLE 15 NORTH AMERICA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 16 NORTH AMERICA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 17 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 18 NORTH AMERICA SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 19 NORTH AMERICA SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 20 NORTH AMERICA BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 21 NORTH AMERICA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 22 NORTH AMERICA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 23 NORTH AMERICA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 24 NORTH AMERICA CYTOKINESPRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 25 NORTH AMERICA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 26 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (UNITS)

TABLE 28 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (ASP)

TABLE 29 NORTH AMERICA SAXAGLIPTIN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, REGION, 2017-2028 (USD MILLION)

TABLE 30 NORTH AMERICA ENOXAPARIN SODIUM IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 31 NORTH AMERICA RUFINAMIDE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 32 NORTH AMERICA TAMOXIFEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 33 NORTH AMERICA ARTEMISININ IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 34 NORTH AMERICA LOSARTAN POTASSIUM IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 35 NORTH AMERICA NAPROXEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 36 NORTH AMERICA IBUPROFEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 37 NORTH AMERICA ACETAMINOPHEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 38 NORTH AMERICA SODIUM CHLORIDE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 39 NORTH AMERICA OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 40 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA PRESCRIPTION DRUGS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 42 NORTH AMERICA OVER-THE-COUNTER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 43 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 44 NORTH AMERICA CLINICAL IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 45 NORTH AMERICA OVER-THE-COUNTER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 46 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 47 NORTH AMERICA LOW-TO-MODERATE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 48 NORTH AMERICA POTENT-TO-HIGHLY POTENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 49 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 50 NORTH AMERICA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 51 NORTH AMERICA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 52 NORTH AMERICA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 53 NORTH AMERICA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 54 NORTH AMERICA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 55 NORTH AMERICA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 56 NORTH AMERICA GASTROENTEROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 57 NORTH AMERICA GASTROENTEROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 58 NORTH AMERICA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 59 NORTH AMERICA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 60 NORTH AMERICA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 61 NORTH AMERICA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 62 NORTH AMERICA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 63 NORTH AMERICA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 64 NORTH AMERICA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 65 NORTH AMERICA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 66 NORTH AMERICA OPHTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 67 NORTH AMERICA OPHTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 68 NORTH AMERICA OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 69 NORTH AMERICA OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 70 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 71 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 72 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 73 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 74 NORTH AMERICA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 75 NORTH AMERICA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 76 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 77 NORTH AMERICA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 78 NORTH AMERICA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 79 NORTH AMERICA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 80 NORTH AMERICA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 81 NORTH AMERICA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 82 NORTH AMERICA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 83 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 84 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 85 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 86 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 87 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 88 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 89 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 90 NORTH AMERICA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 91 NORTH AMERICA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 92 NORTH AMERICA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 93 NORTH AMERICA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 94 NORTH AMERICA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 95 NORTH AMERICA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 96 NORTH AMERICA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 97 NORTH AMERICA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 98 NORTH AMERICA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 99 NORTH AMERICA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 100 U.S.ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 101 U.S.ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 102 U.S.ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 103 U.S.TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 104 U.S.TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 105 U.S.ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 106 U.S.SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 107 U.S.TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 108 U.S.PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 109 U.S.MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 110 U.S.CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 111 U.S.EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 112 U.S.ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 113 U.S. ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 114 U.S. ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 115 U.S.ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 116 U.S.ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 117 U.S.ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 118 U.S.ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 119 U.S.CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 120 U.S.CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 121 U.S.ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 122 U.S.GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 123 U.S.PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 124 U.S.ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 125 U.S.NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 126 U.S.ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 127 U.S.OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 128 U.S.OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 129 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 130 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 131 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 132 CANADA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 133 CANADA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 134 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 135 CANADA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 136 CANADA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 137 CANADA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 138 CANADA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 139 CANADA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 140 CANADA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 141 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 142 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 143 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 144 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 145 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 146 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 147 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 148 CANADA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 149 CANADA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 150 CANADA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 151 CANADA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 152 CANADA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 153 CANADA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 154 CANADA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 155 CANADA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 156 CANADA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 157 CANADA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 158 MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 159 MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 160 MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 161 MEXICO TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 162 MEXICO TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 163 MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 164 MEXICO SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 165 MEXICO TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 166 MEXICO PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 167 MEXICO MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 168 MEXICO CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 169 MEXICO EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 170 MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 171 MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 172 MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 173 MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 174 MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 175 MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 176 MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 177 MEXICO CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 178 MEXICO CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 179 MEXICO ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 180 MEXICO GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 181 MEXICO PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 182 MEXICO ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 183 MEXICO NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 184 MEXICO ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 185 MEXICO OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 186 MEXICO OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions